Department of Biostatistics, Harvard University T H Chan School of Public Health, Boston, Massachusetts, USA.
Department of Medicine, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.
BMJ Open. 2023 Sep 13;13(9):e072810. doi: 10.1136/bmjopen-2023-072810.
To evaluate the synergistic effects created by fine particulate matter (PM) and corticosteroid use on hospitalisation and mortality in older adults at high risk for cardiovascular thromboembolic events (CTEs).
A retrospective cohort study using a US nationwide administrative healthcare claims database.
A 50% random sample of participants with high-risk conditions for CTE from the 2008-2016 Medicare Fee-for-Service population.
Corticosteroid therapy and seasonal-average PM.
Incidences of myocardial infarction or acute coronary syndrome (MI/ACS), ischaemic stroke or transient ischaemic attack, heart failure (HF), venous thromboembolism, atrial fibrillation and all-cause mortality. We assessed additive interactions between PM and corticosteroids using estimates of the relative excess risk due to interaction (RERI) obtained using marginal structural models for causal inference.
Among the 1 936 786 individuals in the high CTE risk cohort (mean age 76.8, 40.0% male, 87.4% white), the mean PM exposure level was 8.3±2.4 µg/m and 37.7% had at least one prescription for a systemic corticosteroid during follow-up. For all outcomes, we observed increases in risk associated with corticosteroid use and with increasing PM exposure. PM demonstrated a non-linear relationship with some outcomes. We also observed evidence of an interaction existing between corticosteroid use and PM for some CTEs. For an increase in PM from 8 μg/m to 12 μg/m (a policy-relevant change), the RERI of corticosteroid use and PM was significant for HF (15.6%, 95% CI 4.0%, 27.3%). Increasing PM from 5 μg/m to 10 μg/m yielded significant RERIs for incidences of HF (32.4; 95% CI 14.9%, 49.9%) and MI/ACSs (29.8%; 95% CI 5.5%, 54.0%).
PM and systemic corticosteroid use were independently associated with increases in CTE hospitalisations. We also found evidence of significant additive interactions between the two exposures for HF and MI/ACSs suggesting synergy between these two exposures.
评估细颗粒物(PM)和皮质类固醇使用对心血管血栓栓塞事件(CTE)高危老年人住院和死亡的协同作用。
使用美国全国性医疗保健索赔数据库进行的回顾性队列研究。
来自 2008-2016 年 Medicare 按服务收费人群中具有 CTE 高危条件的参与者的 50%随机样本。
皮质类固醇治疗和季节性平均 PM。
心肌梗死或急性冠状动脉综合征(MI/ACS)、缺血性卒中和短暂性脑缺血发作、心力衰竭(HF)、静脉血栓栓塞、心房颤动和全因死亡率的发生率。我们使用因果推断的边缘结构模型估计相对过量风险归因于相互作用(RERI)来评估 PM 和皮质类固醇之间的附加相互作用。
在高 CTE 风险队列的 1936786 名个体中(平均年龄 76.8 岁,40.0%为男性,87.4%为白人),PM 暴露水平平均为 8.3±2.4μg/m,37.7%在随访期间至少有一次全身皮质类固醇处方。对于所有结局,我们观察到皮质类固醇使用和 PM 暴露增加与风险增加相关。PM 与一些结局呈非线性关系。我们还观察到皮质类固醇使用和 PM 之间存在相互作用的证据。对于 PM 从 8μg/m 增加到 12μg/m(政策相关变化),HF 的皮质类固醇使用和 PM 的 RERI 有统计学意义(15.6%,95%CI 4.0%,27.3%)。PM 从 5μg/m 增加到 10μg/m 导致 HF(32.4;95%CI 14.9%,49.9%)和 MI/ACSs(29.8%;95%CI 5.5%,54.0%)发生率的 RERI 有统计学意义。
PM 和全身皮质类固醇的使用与 CTE 住院的增加独立相关。我们还发现这两种暴露之间存在显著的附加相互作用的证据,表明这两种暴露之间存在协同作用。